Ugly Numbers
October 28, 2010
How bad are the job losses in pharma? How long will they last? As a starting point, every month brings new, grim numbers from Challenger, Gray & Christmas, a Chicago firm that specializes in executive recruiting.
Recent Challenger data suggest that, at the moment, the job losses in pharma are intensifying relative to other industries. In 2010,…more...
October Special Report
September 17, 2010
Is the most time-honored business model in clinical trial outsourcing out of step with our era?
Most contract research organizations (CRO) charge on the basis of time and materials. Such companies resemble construction firms that erect skyscrapers. If the design of the skyscraper changes, the builder adjusts its fee. If more steel is needed, that goes on…more...
Compliance? Huh?
August 05, 2010
History records that after her husband was assassinated, someone asked Mrs. Abraham Lincoln about the theatrical production she had just seen.
With all deference to Mrs. Lincoln, we are in a similarly stunned state of mind after talking to Kit Howard, principal of Kestrel Consultants. Based in Michigan, with a Canadian's calm demeanor, Howard speaks in methodical,…more...
Temple, O'Neill At DIA
July 12, 2010
As the industry scrambles to find the patients it needs outside the U.S., the organizers of the 2010 annual Drug Information Association (DIA) in Washington, D.C. decided to assemble the sort of luminary-packed panel discussions that only the DIA can present.
The session on multi-regional trials began with Doug Peddicord, executive director of the Association of Clinical…more...
2010 Keynote Address
FDA commissioner Margaret Hamburg addresses the DIA meeting in Washington, D.C.
Thin The Herd
Norman Goldfarb discusses recent industry trends and his upcoming conference in Boston in May.
U.S. Slips On Mega Projects
As the new year begins, some reflections on the biggest clinical trials of the new year.
Fearless With Sponsors
A productive and independent Florida site works lean and doesn’t apologize for being in business.
Private Equity Buyer
The owners of Chiltern are buying MDS Pharma’s six central labs.
Knowledge Gap
Is the industry using conferences and publications correctly, or is it just reinventing things that should more properly be refined?
Staying On Track
Icon discusses its philosophy and the roots of its recent success.
